Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Doxofylline in Clinically Stable COPD Patients
NCT04238221Phase 4Not yet recruiting
- Sponsor
- University of Milan
- Start
- Dec 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, single-blind trial of doxofylline in chronic obstructive pulmonary disease (COPD) (2 arms), sponsored by University of Milan. Primary endpoint: Forced Expiratory Volume in 1 second at 8 weeks. Planned start Dec 2026; status: not yet recruiting.
02
Drugs
doxofylline
03
Conditions
chronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on NCT04238221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04238221.